Specialist health sciences university leading in tissue engineering, epilepsy research, and precision medicine with global surgical programs.
RCSI is a specialist health sciences university in Dublin focused on biomedical research, particularly tissue engineering, drug delivery, and neurological disorders. They develop biomaterial scaffolds for bone and cartilage repair, investigate epilepsy mechanisms and treatments, and advance precision medicine approaches for cancer and neurodegenerative diseases. They also run significant surgical capacity-building programs in low-resource settings, notably in sub-Saharan Africa, and train the next generation of biomedical researchers through a strong portfolio of Marie Skłodowska-Curie fellowships and training networks.
Core strength across projects like BONDS (bilayered on-demand scaffolds), miRaColl (miRNA-activated cartilage scaffolds), CarBon (cartilage-to-bone transitions), InjectCHA, VascColl, and LAF-GRAFT.
Growing cluster including EpiMIRgen (miR-124 in epilepsy), EpiPur (P2X7R axis in drug-refractory epilepsy), PurinesDX (purinergic receptors in neuroinflammation), and iHEAR (psychotic experiences in young people).
COLOSSUS (precision medicine for metastatic colorectal cancer), GLIOTRAIN (glioblastoma training network), MEL-PLEX (melanoma complexity), and BigMedilytics (big data oncology analytics).
NanoCap (polypeptide nanoparticle drug delivery platform), EsterPep (polyester/polypeptide hybrid biomaterials), and related scaffold fabrication work in BONDS using freeze-drying and plasmid-DNA delivery.
Recent keyword clusters around glycans, sugars, carbohydrates, and bionano interactions/corona studies suggest a growing research direction in how biological nano-interfaces behave.
SURG-Africa (EUR 1.57M, coordinated by RCSI) focused on scaling safe surgery for district hospitals across Africa, reflecting RCSI's institutional mission in global health.
In the early H2020 period (2014–2018), RCSI's research centered on tissue engineering and regenerative medicine — cartilage repair, skin therapies, biomaterial scaffolds, and disease modeling using genetic engineering. From 2018 onward, a clear shift emerged toward epilepsy research, glycoscience, 3D printing of biomaterials, and polypeptide-based delivery systems. The portfolio also broadened into precision oncology (COLOSSUS) and mental health (iHEAR), indicating a move from foundational biomaterials work toward more translational, disease-specific applications.
RCSI is moving from general biomaterials development toward disease-targeted applications — especially in epilepsy, neuroinflammation, and precision oncology — making them an increasingly strong partner for translational medicine consortia.
RCSI overwhelmingly leads its projects: 47 of 63 H2020 projects were coordinated by RCSI, a remarkably high ratio for a university. Their heavy use of MSCA Individual Fellowships (28 projects) means many projects are small, single-PI efforts hosted at RCSI, which inflates the coordinator count but also demonstrates their strength as a research host institution. When they join larger consortia (DRIVE, BIORIMA, BigMedilytics), they typically contribute specialist biomedical expertise rather than infrastructure, and their 343 unique partners across 46 countries show they are well-connected and open to diverse collaboration.
RCSI has collaborated with 343 unique partners across 46 countries, making them one of the most broadly networked health sciences institutions in Ireland. Their reach extends well beyond Europe, with projects spanning global health initiatives in Africa alongside deep European research partnerships.
RCSI occupies a rare position as a specialist surgical and health sciences university (not a general university) with deep bench strength in biomaterials and tissue engineering. Their exceptionally high coordination rate and strong MSCA fellowship track record make them an attractive host for researchers and a reliable consortium leader. The combination of fundamental biomaterials science, clinical translation capability through their hospital network, and global health engagement in Africa gives them a breadth that few peer institutions can match.
